Trial Profile
A retrospective observational study of safety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jun 2017
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 15 Jun 2017 New trial record
- 01 May 2017 Results published in the Current Medical Research and Opinion